Mega Lifesciences Public Company Limited

$ 35.00 -2.10 %

Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, was founded in 1982 and is based in Bangkok, Thailand. This diversified healthcare enterprise is primarily involved in the production, promotion, and sale of an extensive array of health-related products, encompassing dietary supplements, over-the-counter (OTC) and prescription pharmaceuticals, herbal remedies, vitamins, and fast-moving consumer goods. The company organizes its activities across three main divisions: Brands, Distribution, and Original Equipment Manufacture (OEM). Its vast product portfolio includes a wide selection of complementary medicines designed for various needs, such as bone and joint support, children's health, diabetes and heart care, herbal solutions, liver and digestive well-being, skin health, weight management, overall vitality, specific men's and women's health products, and sports nutrition. Additionally, the pharmaceutical segment provides OTC solutions for gastrointestinal issues and pain, alongside a comprehensive range of prescription drugs targeting therapeutic areas like iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain management, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its core product lines, Mega Lifesciences offers logistical and marketing services for goods manufactured by other companies. It also operates wellness centers and engages in software design, development, and related service provisions. The company maintains a strong global footprint, with operations spanning the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States regions.

CEO: Vivek Dhawan - https://www.megawecare.com

Price objectif

-

Recommandation

-

DCF

$ 60.94

Loading data...

MEGA-R.BK vs S&P500

Loading data...

No data available.

Quick ratio

1.65

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

14.83

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

2.36

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

20.49 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

20.09 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.75

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.06

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

2.97

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

67.50 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
5.97 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.84 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.04 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.